Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Ultragenyx Pharmaceutical Inc shares valued at $89,923 were sold by Sanders Corazon (Corsee) D. on Jun 20 ’25. At $37.39 per share, Sanders Corazon (Corsee) D. sold 2,405 shares. The insider’s holdings dropped to 15,344 shares worth approximately $0.57 million following the completion of this transaction.
Also, CORAZON D. SANDERS purchased 2,405 shares, netting a total of over 89,923 in proceeds.
Before that, Crombez Eric had sold 520 shares from its account. In a trade valued at $20,405, the EVP and Chief Medical Officer traded Ultragenyx Pharmaceutical Inc shares for $39.24 each. Upon closing the transaction, the insider’s holdings decreased to 520 shares, worth approximately $2.66 million.
As published in their initiating research note from William Blair on May 28, 2025, Ultragenyx Pharmaceutical Inc [RARE] has been an Outperform. Analysts at Goldman upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in early June. As of April 22, 2024, RBC Capital Mkts has initiated its “an Outperform” rating for RARE. Earlier on December 08, 2023, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for RARE stock.
Analyzing RARE Stock Performance
On last trading session,, Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] plunged -0.83% to $37.12. The stock’s lowest price that day was $36.47, but it reached a high of $37.85 in the same session. During the last five days, there has been a drop of approximately -0.62%. Over the course of the year, Ultragenyx Pharmaceutical Inc shares have dropped approximately -5.83%. Shares of the company reached a 52-week high of $46.50 on 02/06/25 and a 52-week low of $29.59 on 04/09/25.
Support And Resistance Levels for Ultragenyx Pharmaceutical Inc (RARE)
According to the 24-hour chart, there is a support level at 36.41, which, if violated, would cause prices to drop to 35.70. In the upper region, resistance lies at 37.84. The next price resistance is at 38.56. RSI (Relative Strength Index) is 51.86 on the 14-day chart, showing neutral technical sentiment.
Is Ultragenyx Pharmaceutical Inc subject to short interest?
Stocks of Ultragenyx Pharmaceutical Inc saw a sharp rise in short interest on 2025-06-13 jumping by 0.19 million shares to 6.08 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 5.89 million shares. A jump of 3.11% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.87 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.87.
Which companies own the most shares of Ultragenyx Pharmaceutical Inc (RARE)?
In terms of Ultragenyx Pharmaceutical Inc share price expectations, FactSet research, analysts set an average price target of 89.5 in the next 12 months, up nearly 139.11% from the previous closing price of $37.43. Analysts anticipate Ultragenyx Pharmaceutical Inc stock to reach 115 by 2025, with the lowest price target being 64. In spite of this, 16 analysts ranked Ultragenyx Pharmaceutical Inc stock as Buy at the end of 2025. On June 14, 2023, Credit Suisse assigned a price target of “an Outperform” to the stock and resumed coverage with a $96.
